Boditech Med Executive and Leadership Team

Yule Choi, the Chief Executive Officer at Boditech Med, directs the overarching corporate strategy and global market expansion initiatives. The Chief Executive Officer manages the alignment of diagnostic product development with international healthcare requirements, ensuring that the company maintains a competitive edge in point-of-care testing. By overseeing the integration of 85 biomarkers into clinical workflows, Choi drives operational efficiency across diverse regional markets. This leadership role involves constant collaboration with the Board to secure long-term financial growth and sustainable innovation. Yule Choi monitors the performance of diagnostic solutions in capillary and venous blood testing, guaranteeing that quality standards meet the needs of clinicians worldwide. Through rigorous oversight of resource allocation, the Chief Executive Officer optimizes the company's ability to deliver rapid, accurate diagnostic results to patients in 120 countries, thereby solidifying the firm's position as a leader in the global in-vitro diagnostics industry.

Eui-Yul Choi, the Co-Founder & Chief Executive Officer at Boditech Med, architects the long-term vision and foundational business model for the organization. The Co-Founder & Chief Executive Officer focuses on scaling the company's diagnostic infrastructure to support the increasing demand for point-of-care testing solutions. By steering the strategic direction of the firm, Eui-Yul Choi ensures that the development of new biomarkers remains consistent with the company's mission to improve health outcomes. This executive role involves managing high-level partnerships and fostering an environment of innovation that spans across the global operations. The Co-Founder & Chief Executive Officer evaluates market trends to identify new opportunities for growth in the in-vitro diagnostic sector. Through the implementation of robust management frameworks, Choi maintains the integrity of the company's research-driven approach, ultimately ensuring that the organization continues to provide essential diagnostic tools to clinicians and patients in 120 countries.

Euiyul Choi, the Founder & Chief Executive Officer at Boditech Med, drives the core mission of enhancing quality of life through advanced diagnostic technology. The Founder & Chief Executive Officer oversees the company's commitment to excellence in in-vitro diagnostics, ensuring that every product meets the highest standards of clinical accuracy. By managing the strategic deployment of resources, Euiyul Choi facilitates the expansion of the company's footprint in international markets. This leadership position requires constant engagement with stakeholders to align business objectives with the evolving needs of the global healthcare community. The Founder & Chief Executive Officer monitors the efficacy of diagnostic solutions, focusing on the integration of plasma and blood testing capabilities into modern medical practices. Through the cultivation of a culture centered on scientific rigor, Choi ensures that the company remains at the forefront of the point-of-care testing industry, providing reliable diagnostic support to clinicians across 120 countries.

Keith Nahm, the Chief Technology Officer at Boditech Med, directs the research and development of innovative in-vitro diagnostic solutions. The Chief Technology Officer oversees the technical architecture behind the company's 85 biomarkers, ensuring that all testing platforms provide precise results for capillary, venous, and plasma samples. By managing the engineering teams, Nahm drives the creation of new diagnostic tools that address the complex requirements of clinicians in 120 countries. This leadership role involves collaborating with the executive team to translate scientific breakthroughs into scalable, market-ready products. Keith Nahm evaluates emerging technologies to maintain the company's status as a global leader in point-of-care testing. Through the continuous refinement of diagnostic hardware and software, the Chief Technology Officer optimizes the performance of the company's product portfolio, ensuring that all technological advancements directly contribute to improved patient care and the overall growth of the organization's diagnostic capabilities.